Laruparetigene zosaparvovec

N/A

Report date: 2026/04/08 20:02:35

Base Information

Drug NameLaruparetigene zosaparvovec
Drug Alias NamerAAV2tYF-GRK1-RPGRrAAV2tYF-GRK1-hRPGRcoAGTC-501BIIB088
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector > AAV2 vector
Mechanisms of ActionRPGR gene transference
TargetsX-linked retinitis pigmentosa GTPase regulator
Therapy Area/IndicationsRetinitis Pigmentosa
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesApplied Genetic Technologies Corporation
China Registration ClassN/A

Develop Information

Active CompaniesBeacon Therapeutics Holdings Ltd
Inactive CompaniesBiogen Inc
Active IndicationsRetinitis Pigmentosa
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A